A comparative clinical study of MYMD-1 and three FDA-approved JAK inhibitor drugs for the treatment of autoimmune and inflammatory diseases
Latest Information Update: 02 Aug 2021
At a glance
- Drugs Isomyosamine (Primary)
- Indications Autoimmune disorders; Inflammation
- Focus Adverse reactions
- 02 Aug 2021 New trial record
- 27 Jul 2021 According to a MyMD Pharmaceuticals media release, the company has announced the data from this study.
- 27 Jul 2021 According to a MyMD Pharmaceuticals media release, this study is conducted by the Eurofins Discovery.